BOSTON – Mintz announced today that it advised Hopewell Therapeutics, a biotechnology company with a differentiated lipid nanoparticle platform harnessing unique ionizable lipid chemistry, in its Seed Financing of up to $25 million. The funds will enable Hopewell to advance the development of genomic medicines based on its differentiated tissue-targeted Lipid Nanoparticle (ttLNP) platform through both internal pipeline programs and external partnerships.

Investors included Mass Ave Capital, 5Y Capital and HIKE Capital. The funding was carried out in multiple stages, with a significant portion of funds already received by the company, along with additional commitments from existing investors.

Hopewell’s ttLNP platform was transformed by a decade of research and foundational intellectual property from Tufts University, where Founder and Chief Technology Officer, Qiaobing Xu, Ph.D., is a professor of Biomedical Engineering. Hopewell holds exclusive licenses to the Tufts-derived ttLNP intellectual property estate for use in a broad field of clinical and commercial applications.

More information about the financing can be obtained from Hopewell’s announcement.

The Mintz Venture Capital and Emerging Companies team was led by Joshua Fox, a Member of the firm’s Boston office, and included Will Bussiere, Jr. and Dayna Mucci.

Mintz is one of the leading law firms to the life sciences industry. The firm’s attorneys advise thousands of businesses and other organizations across the sector’s ecosystem—from start-ups and emerging growth companies to large public companies as well as venture capital firms, investment banks, and research and academic institutions—on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters. Learn more about Mintz’s Life Sciences Practice here.